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Depression and end-stage renal 
disease: a therapeutic challenge
Fredric O. Finkelstein1,2,3, Diane Wuerth2, Laura K. Troidle1,2,3  
and Susan H. Finkelstein2,3
Hedayati et al. document a 26.5% incidence of clinical depression 
and a strong association between depression and hospitalizations 
and mortality in hemodialysis patients. We can no longer ignore the 
impact of depression on end-stage renal disease patients. Appropriate 
therapeutic regimens and trials need to be explored.
Kidney International (2008) 74, 843–845. doi:10.1038/ki.2008.222
There has recently been an increasing 
interest in the assessment of the psychoso-
cial status of patients with end-stage renal 
disease (ESRD). This interest has been 
stimulated by the recognition in several 
studies that various psychosocial factors 
can impact the morbidity and mortality 
of ESRD patients.1,2 The majority of these 
studies have been performed by screening 
of cohorts of ESRD patients with standard-
ized questionnaires and then demonstrat-
ing a relationship between the scores on 
these instruments and various outcomes. 
Perhaps the largest studies to document 
this association come from the Dialysis 
Outcomes and Practice Patterns Study 
(DOPPS) database.1,2 These investigators 
have shown a clear correlation between 
both hospitalization and mortality rates 
and the physical and mental component 
summary scores of the SF-36, as well as the 
presence of depressive symptoms (as meas-
ured by two specific questions on the SF-36 
and the Center for Epidemiological Stud-
ies Depression Screening Index (CES-D) 
questionnaire).1,2 The latter association 
is of particular importance, as depression 
is generally agreed to be the most com-
mon psychological problem presented by 
dialysis patients. In various studies, it has 
been suggested that 20%–30% of patients 
with renal failure suffer from clinical 
depression.3,4 Dialysis patients frequently 
exhibit a depressive affect (pessimism, 
anhedonia, sadness, complaints of feeling 
helpless and hopeless). These symptoms 
may result in changes in sleep, concentrat-
ing ability, appetite, activity level, and libido 
and contribute to problems with mari-
tal and family relationships and reduced 
occupational activity. But it is important to 
distinguish between the presence of depres-
sive symptoms and a diagnosis of clinical 
depression. Self-administered question-
naires are useful to screen patients for the 
presence of depressive symptoms, but the 
diagnosis of clinical depression requires a 
careful, structured patient interview.
Thus, a new study by Hedayati et al.5 
(this issue) is of particular importance. This 
is a prospective study in which a cohort 
of hemodialysis patients were screened 
with the Structured Clinical Interview 
for Diagnostic and Statistical Manual of 
Mental Disorders (SCID). Thus, a diagno-
sis of clinical depression was established 
with direct interviewing; the authors did 
not rely on screening questionnaires to 
indicate the presence of depressive symp-
toms, which might suggest the presence 
of clinical depression. Importantly, these 
investigators confirm what has been sug-
gested previously with questionnaires or 
clinical impressions; a clinical diagnosis 
of depression was established in 26.5% 
of patients. In terms of outcomes, in an 
adjusted model, the presence of depression 
was associated with a 2.07 (95% confidence 
interval 1.1–3.9) relative risk of hospitaliza-
tion or death. Interestingly, in the DOPPS 
studies, CES-D scores of 15–30 (the highest 
group) were associated with a 1.8 relative 
risk of death.1 These strong associations 
between depression and poor medical out-
comes are consistent with findings in other 
disease states.6,7 For example, in patients 
with diabetes with elevated CES-D scores 
(>16, similar to the high range observed in 
the DOPPS), there is a 1.6 relative risk of 
death compared with that in patients with 
lower scores.6 And a recent meta –analysis 
emphasized the significant impact of both 
depressive symptoms and clinical depres-
sion on mortality rates in patients with 
coronary heart disease.7
Why should this strong association 
between depression and morbidity and 
mortality exist for ESRD patients? The like-
lihood of elective withdrawal from dialysis 
is significantly increased in ESRD patients 
with depressive symptoms.1 Compliance 
issues may certainly contribute; patients 
with cardiac disease reporting depressive 
symptoms (Patient Health Questionnaire 
scores >10) are threefold more likely to 
report poor adherence to medication regi-
mens than patients with Patient Health 
Questionnaire scores of 0–3.8 This reduced 
compliance may be responsible for the 
2.7-fold greater risk of peritonitis in perito-
neal dialysis patients with Beck Depression 
Inventory (BDI) scores of at least 11.9 And 
depression has been clearly linked to signif-
icant elevations of various serum inflam-
matory markers.10–12 For example, a strong 
association between major depression and 
elevated C-reactive protein levels has been 
demonstrated in numerous studies. Data 
from the Third National Health and Nutri-
tion Examination Survey (NHANES III) 
study have shown that a history of major 
depression is associated with an elevated 
C-reactive protein level (odds ratio 1.64; 
95% confidence interval 1.20–2.24). The 
Women’s Ischemia Syndrome Evalua-
tion (WISE) study has emphasized that 
women with depression have 70% higher 
C-reactive protein (P = 0.0008) and 25% 
higher interleukin-6 (P = 0.04) levels than 
women without depression.10 Do the 
elevated inflammatory markers contribute 
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to the association between depression and 
cardiovascular disease? The WISE study 
addressed this question and found that 
although depression was a significant pre-
dictor of cardiovascular disease (hazard 
ratio 2.58, P = 0.0009), this association was 
only in part explained by the elevations of 
the inflammatory markers, suggesting that 
other factors could contribute to this asso-
ciation.10
This relationship between depression 
and poor outcomes obviously raises the 
question of the potential benefit of treat-
ing depression. Can the treatment of 
depression not only alleviate depressive 
symptoms and improve patients’ moods but 
also improve medical outcomes? Remark-
ably, there are few studies examining the 
treatment of depression in ESRD patients. 
Recent reports have suggested that depres-
sive symptoms can be ameliorated by psy-
chiatric counseling, cognitive-behavioral 
therapy, and/or medications.13,14 How-
ever, the treatment of clinical depression 
in dialysis patients presents various obsta-
cles. First, it is difficult (logistically and 
financially) to encourage patients to pur-
sue an appropriate evaluation. And among 
those patients who do and are diagnosed 
with clinical depression, it is difficult to 
get them to complete a prescribed course 
of medication or psychotherapy.13 Many 
patients are reluctant to take additional 
medications, the medications themselves 
may have side effects, and the dialysis 
regimen itself imposes time constraints 
on patients’ willingness to obtain appro-
priate counseling. Thus, in our peritoneal 
dialysis unit, we systematically screened all 
patients for depression with the BDI ques-
tionnaire, referred patients with BDI scores 
≥11 for interviews, and then recommended 
treatment (where appropriate) for those 
patients who were judged to have clini-
cal depression.9 Only half of patients with 
BDI scores ≥11 agreed to interviewing to 
confirm a diagnosis of clinical depression, 
and of those patients who agreed to be 
interviewed and had clinical depression, 
only half completed a 12-week course of 
antidepressant therapy. Reasons for not 
completing therapy were multifactorial 
and included intercurrent medical prob-
lems, medication side effects, substance 
abuse, and DSM-IV–axis 2 personality 
disorders.13 But in those patients who did 
complete a 12-week course of therapy, BDI 
scores decreased from a mean ± standard 
deviation of 17.4 ± 6.6 to 8.4 ± 3.0.13
Thus, planning a treatment program 
for ESRD patients with clinical depres-
sion is difficult and will complicate any 
randomized trial. Given the number of 
patients with ESRD and the high inci-
dence of clinical depression noted by 
Hedayati et al.,5 psychological counseling 
or cognitive−behavioral therapy presents 
logistical and staffing problems. And the 
medications used to treat depression, while 
alleviating the symptoms of the mood dis-
order, may contribute to other adverse 
outcomes, such as increased falls in elderly 
patients and a variety of side effects.15,16 
These issues need to be kept in mind as 
therapeutic trials are designed. Despite 
these problems, it is clear that there is a 
need for therapeutic trials to be planned to 
examine whether the treatment of depres-
sion impacts the medical outcomes of 
ESRD patients.
On a clinical note, while we await the 
results of therapeutic trials, it would seem 
to be important for each facility to develop 
a framework to systematically screen 
patients for depression, evaluate patients 
for the presence of clinical depression, and 
then develop algorithms for the manage-
ment of depression (Figure 1). It remains 
uncertain whether medical outcomes will 
improve, but it is clear that depressive 
symptoms can be lessened, thus improv-
ing the quality of life of the patient and his 
or her family.12,13 Developing such treat-
ment algorithms remains challenging, 
given staffing patterns, the limited avail-
ability of the social worker in being able to 
provide individual and family counseling, 
and the limited psychological training of 
the dialysis staff. But it is an issue that must 
be pursued; creative, innovative approaches 
will be needed. Given the data presented 
by Hedayati et al.5 and others, we can no 
longer ignore the impact of depression on 
ESRD patients. Appropriate therapeutic 
regimens need to be explored!
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figure 1 | Proposed schema for screening for and treating depression in a cohort of  
ESRD patients.
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Will there be an epidemic of HIV-
related chronic kidney disease in 
sub-Saharan Africa? Too soon to tell
Kara K. Wools-Kaloustian1 and Samir K. Gupta1
Most of what we know about HIV-related kidney disease comes 
from developed settings. However, the greatest population at risk 
resides in resource-limited areas where monitoring and treatment for 
kidney dysfunction are outside the scope of medical practice. More 
epidemiologic and prevention research is sorely needed.
Kidney International (2008) 74, 845–847. doi:10.1038/ki.2008.326
The pathobiology and epidemiology of 
HIV-associated nephropathy (HIVAN) 
have been well described in developed, 
Western countries.1 HIV-1 can infect renal 
tissue and initiate the cascade of histologic 
abnormalities of HIVAN that subsequently 
results in the classic clinical phenotype of 
nephrotic-range proteinuria and rapid dete-
rioration in renal function. Importantly, 
HIV-1 replication continues in this renal 
reservoir despite effective suppression of 
plasma viremia with antiretroviral therapy.2 
Fortunately, it appears that HIVAN may be 
reversible once antiretroviral therapy is 
initiated. In fact, a recently published large-
cohort study of HIV-infected patients in the 
United States demonstrated that renal func-
tion generally improves with antiretroviral 
therapy, with the greatest improvement in 
those with the lowest glomerular filtration 
rate prior to treatment initiation.3
What is unique about HIVAN is that 
it predominantly affects those of African 
descent.1 However, despite the availability of 
potent antiretroviral therapy as a treatment 
for HIVAN, mathematical models suggest 
that the prevalence of end-stage renal disease 
requiring renal replacement therapy will still 
exponentially increase in the United States.4 
This apparent paradox is primarily the result 
of an increasing and disproportionate infec-
tion rate in African Americans, many of 
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whom may develop severe nephropathy 
while not knowing of their HIV-positive 
status or having access to care.
Given the strong predisposition toward 
the development of HIVAN in blacks, it 
would seem reasonable to presume that 
the HIV epidemic in sub-Saharan Africa 
will soon lead to an additional epidemic of 
chronic kidney disease. There has been a 
growing anxiety and fear of this possibility 
for several reasons. First, limited clinical 
resources in most African settings have pre-
cluded simple laboratory testing for renal 
dysfunction, so monitoring for kidney dis-
ease may not be feasible. Second, dialysis is 
not available in most settings, so there is no 
effective treatment strategy for those who 
develop severe kidney disease. Finally, and 
most importantly, there has been a general 
lack of local data on the epidemiology of 
renal disease to help guide programmatic 
decisions on allocation of limited resources 
for diagnostics and treatment.
Without such data, can we reasonably 
extrapolate from our experience in the 
West? Not necessarily. There are several 
theoretical reasons why the prevalence of 
kidney disease in HIV-infected Africans 
and the response to antiretroviral therapy 
may not reflect what has been found in 
developed Western settings. First, most 
HIV-infected North Americans and west-
ern Europeans are infected with HIV-1 
clade B.5 Several different clades and 
recombinant forms of HIV-1 circulate in 
Africa. Clade C predominates in eastern 
and southern Africa, whereas other clades 
and recombinant forms of HIV-1 are found 
in central and western Africa. Furthermore, 
HIV type 2 (HIV-2) is also frequently 
found in some parts of western Africa. It 
appears that the rate of HIV disease pro-
gression may depend on the infecting clade 
or type.5 Thus, it is possible that differences 
in these clades or strains may result in dif-
ferences in the replication capacities within 
the isolated renal reservoir and thus lead 
to a diversity of clinical presentations. 
For example, our group found in a cross-
sectional study of untreated HIV-infected 
patients in western Kenya (typically HIV-1 
clade C) a 6% prevalence of proteinuria.6 
Although high compared with that of the 
general population, this prevalence rate is 
substantially lower than that found in HIV-
infected cohorts in the United States.7
